Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BFRANASDAQ:EVFMNASDAQ:KALANASDAQ:NEPTNASDAQ:SLGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRABiofrontera$2.60$2.95$2.09▼$7.54$73.73M1.0227,512 shs7,263 shsEVFMEvofem Biosciences$0.01$0.02$0.01▼$4.36$730K-1.12845,148 shs182,360 shsKALAKALA BIO$6.77-1.0%$7.46$5.10▼$19.35$19.26M-1.8514,034 shs9,250 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsSLGLSol-Gel Technologies$0.94+10.5%$1.04$0.79▼$4.20$23.87M1.3335,279 shs4,553 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRABiofrontera0.00%0.00%0.00%0.00%0.00%EVFMEvofem Biosciences+3.68%-11.04%-21.23%-64.12%-99.64%KALAKALA BIO-1.02%-8.02%-12.31%-7.39%-56.82%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-59.18%-99.22%SLGLSol-Gel Technologies+10.23%+6.25%-8.29%-18.19%-75.65%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRABiofronteraN/AN/AN/AN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKALAKALA BIO3.8922 of 5 stars3.55.00.04.41.70.80.0NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies3.6335 of 5 stars3.85.00.00.03.31.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRABiofronteraN/AN/AN/AN/AEVFMEvofem Biosciences2.00HoldN/AN/AKALAKALA BIO3.00Buy$18.00165.88% UpsideNEPTNeptune Wellness SolutionsN/AN/AN/AN/ASLGLSol-Gel Technologies3.50Strong Buy$8.00746.92% UpsideCurrent Analyst RatingsLatest SLGL, NEPT, EVFM, KALA, and BFRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRABiofrontera$36.19M2.04N/AN/A$0.35 per share7.43EVFMEvofem Biosciences$18.22M0.04$1.41 per share0.01($2.64) per share-0.01KALAKALA BIO$3.89M4.91N/AN/A$2.79 per share2.43NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00SLGLSol-Gel Technologies$1.55M16.98N/AN/A$1.67 per share0.57Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRABiofrontera-$14.88M-$0.73N/A∞N/A-59.44%-93.31%-24.02%N/AEVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%4/26/2024 (Estimated)KALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)SLGLSol-Gel Technologies-$27.24M-$1.01N/AN/AN/A-1,331.01%-61.52%-53.75%5/10/2024 (Estimated)Latest SLGL, NEPT, EVFM, KALA, and BFRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 million3/13/2024Q4 2023SLGLSol-Gel Technologies-$0.16-$0.17-$0.01-$0.17$0.27 million$0.45 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRABiofronteraN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRABiofrontera0.131.261.13EVFMEvofem BiosciencesN/A0.130.10KALAKALA BIO5.106.336.33NEPTNeptune Wellness SolutionsN/A0.230.10SLGLSol-Gel TechnologiesN/A9.109.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRABiofrontera60.07%EVFMEvofem Biosciences0.22%KALAKALA BIO24.61%NEPTNeptune Wellness Solutions14.44%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipBFRABiofronteraN/AEVFMEvofem Biosciences0.21%KALAKALA BIO13.40%NEPTNeptune Wellness Solutions5.10%SLGLSol-Gel Technologies66.51%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBFRABiofrontera13828.36 millionN/ANot OptionableEVFMEvofem Biosciences3553.96 million53.85 millionNot OptionableKALAKALA BIO432.82 million2.44 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableSLGLSol-Gel Technologies3627.86 million9.33 millionOptionableSLGL, NEPT, EVFM, KALA, and BFRA HeadlinesSourceHeadlineSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in Marchamericanbankingnews.com - April 15 at 5:40 AMSol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Creamglobenewswire.com - April 1 at 7:00 AMSol Gel Technologies Ltd (SLGL)investing.com - March 23 at 11:58 AMSLGL May 2024 2.500 putfinance.yahoo.com - March 16 at 1:25 PMSol-Gel Technologies: Q4 Earnings Insightsbenzinga.com - March 14 at 1:48 PMSol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 14 at 8:47 AMSol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developmentsfinanznachrichten.de - March 14 at 3:47 AMSol-Gel Reports Full-Year 2023 Financial Results and Corporate Developmentsglobenewswire.com - March 13 at 7:00 AMSol-Gel Technologies Ltd. (SLGL) stock forecast and price targetfinance.yahoo.com - February 28 at 9:43 AMSol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News Summarybenzinga.com - February 22 at 10:05 AMOptimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market Potentialmarkets.businessinsider.com - December 9 at 3:48 AMSol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Studyfinanznachrichten.de - November 30 at 6:30 PMSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Studyfinance.yahoo.com - November 30 at 8:29 AMSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610finance.yahoo.com - November 28 at 9:36 AMIs Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?finance.yahoo.com - November 20 at 7:19 AMSol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48Mmsn.com - November 9 at 5:31 PMSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 7:27 AMZacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologiesfinance.yahoo.com - October 31 at 9:35 AMIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?finance.yahoo.com - October 10 at 10:05 AMSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 30 at 2:55 PMHC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy Recommendationmsn.com - August 15 at 5:07 AMExpert Ratings for Sol-Gel Technologiesmarkets.businessinsider.com - August 11 at 4:26 PMSol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 10 at 2:04 PMSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 9:03 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiofronteraNASDAQ:BFRABiofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.Evofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Sol-Gel TechnologiesNASDAQ:SLGLSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.